APJCP:IL-21联合CEA可提高恶性胸腔积液诊断率

2013-06-20 APJCP dxy

胸腔积液是许多疾病胸膜受累的常见表现,但是如何区分结核性胸腔积液(TPEs)和恶性胸腔积液(MPEs)一直是困扰临床医生的难题。针对这种情况,来自华中科技大学同济医学院卫生部肺疾病重点实验室的徐永健教授等等人进行了一项研究,研究结果在线发表于2012年第13卷第7期的《亚太癌症预防杂志》(Asian Pacific Journal of Cancer Prevention)杂志上。作者发现IL-2

胸腔积液是许多疾病胸膜受累的常见表现,但是如何区分结核性胸腔积液(TPEs)和恶性胸腔积液(MPEs)一直是困扰临床医生的难题。针对这种情况,来自华中科技大学同济医学院卫生部肺疾病重点实验室的徐永健教授等等人进行了一项研究,研究结果在线发表于2012年第13卷第7期的《亚太癌症预防杂志》(Asian Pacific Journal of Cancer Prevention)杂志上。作者发现IL-21联合CEA可以提高恶性胸腔积液的诊断率。

该研究这项研究诣在评估白细胞介素21(IL- 21)和癌胚抗原(CEA)在结核性胸腔积液(TPEs)和恶性胸腔积液(MPEs)中的诊断价值。103例胸腔积液标本中根据临床诊断标准分为TPE组(n = 51)和MPE组(n = 52)。IL- 21的浓度用ELISA法测定。乳酸脱氢酶(LDH),腺苷脱氢酶(ADA)和CEA 水平在所有患者中做了测定。

研究结果表明,在TPE和MPE之间,ADA和CEA 水平存在显著性差异(P <0.01),但LDH 水平未见明显差异(P> 0.05)。相比TPE,在MPE 中IL- 21的浓度明显升高(P <0.01)。以4.32 pg/ml为阈值,IL- 21的灵敏度为76.9%(40/52),特异性为80.4%(41/51)。IL- 21和CEA 联合检测的灵敏度为69.2%(36/52),特异性为92.2%(47/51)。

该研究发现,对于胸腔积液的患者,白细胞介素21(IL- 21)可能是鉴别结核性胸腔积液(TPEs)和恶性胸腔积液(MPEs)的一个潜在预测指标。然而其他指标,如低密度脂蛋白(LDL)和Pro在TPE和MPE中其浓度无显著差异。在结核性胸腔积液(TPEs)和恶性胸腔积液(MPEs)患者中联合检测白细胞介素21(IL- 21)和癌胚抗原(CEA)使诊断更为精确。

Diagnostic value of interleukin 21 and carcinoembryonic antigen levels in malignant pleural effusions.
Abstract
The aim of this study was to evaluate the diagnostic value of interleukin 21 (IL-21) and carcinoembryonic antigen (CEA) in tuberculous pleural effusions (TPEs) and malignant pleural effusions (MPEs). Pleural effusion samples from 103 patients were classified on the basis of diagnosis as TPE (n=51) and MPE (n=52). The concentration of IL-21 was determined by ELISA. Lactate dehydrogenase (LDH), adenosine dehydrogenase (ADA) and CEA levels were also determined in all patients. A significant difference was observed in the levels of ADA and CEA (P<0.01), but not in the levels of LDH (P>0.05) between TPE and MPE. The concentration of IL-21 in MPE was significantly higher compared to TPE (P<0.01). With a threshold value of 4.32 pg/ml, IL-21 had a sensitivity of 76.9% (40/52) and a specificity of 80.4% (41/51). Combined detection of IL-21 and CEA had a sensitivity of 69.2% (36/52) and a specificity of 92.2% (47/51). These two markers can contribute to the differential diagnosis of MPEs.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1778457, encodeId=0c8b1e7845778, content=<a href='/topic/show?id=51f09653ba' target=_blank style='color:#2F92EE;'>#IL-21#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9653, encryptionId=51f09653ba, topicName=IL-21)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=753a39257265, createdName=baoya, createdTime=Wed Aug 28 15:00:00 CST 2013, time=2013-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981624, encodeId=6897198162405, content=<a href='/topic/show?id=87679163e47' target=_blank style='color:#2F92EE;'>#诊断率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91637, encryptionId=87679163e47, topicName=诊断率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3bfe313, createdName=charleshjw, createdTime=Sat Mar 29 16:00:00 CST 2014, time=2014-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488627, encodeId=4f52148862e0d, content=<a href='/topic/show?id=c6af443e2d' target=_blank style='color:#2F92EE;'>#CEA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4437, encryptionId=c6af443e2d, topicName=CEA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce258462097, createdName=shizhenshan, createdTime=Sat Jun 22 07:00:00 CST 2013, time=2013-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506778, encodeId=5efb1506e78ec, content=<a href='/topic/show?id=73fc529444d' target=_blank style='color:#2F92EE;'>#恶性胸腔积液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52944, encryptionId=73fc529444d, topicName=恶性胸腔积液)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d3b9807093, createdName=ssnine, createdTime=Sat Jun 22 07:00:00 CST 2013, time=2013-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626021, encodeId=56c81626021f3, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9652, encryptionId=87369652f3, topicName=IL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea8220955712, createdName=tomyang93, createdTime=Sat Jun 22 07:00:00 CST 2013, time=2013-06-22, status=1, ipAttribution=)]
    2013-08-28 baoya
  2. [GetPortalCommentsPageByObjectIdResponse(id=1778457, encodeId=0c8b1e7845778, content=<a href='/topic/show?id=51f09653ba' target=_blank style='color:#2F92EE;'>#IL-21#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9653, encryptionId=51f09653ba, topicName=IL-21)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=753a39257265, createdName=baoya, createdTime=Wed Aug 28 15:00:00 CST 2013, time=2013-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981624, encodeId=6897198162405, content=<a href='/topic/show?id=87679163e47' target=_blank style='color:#2F92EE;'>#诊断率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91637, encryptionId=87679163e47, topicName=诊断率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3bfe313, createdName=charleshjw, createdTime=Sat Mar 29 16:00:00 CST 2014, time=2014-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488627, encodeId=4f52148862e0d, content=<a href='/topic/show?id=c6af443e2d' target=_blank style='color:#2F92EE;'>#CEA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4437, encryptionId=c6af443e2d, topicName=CEA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce258462097, createdName=shizhenshan, createdTime=Sat Jun 22 07:00:00 CST 2013, time=2013-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506778, encodeId=5efb1506e78ec, content=<a href='/topic/show?id=73fc529444d' target=_blank style='color:#2F92EE;'>#恶性胸腔积液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52944, encryptionId=73fc529444d, topicName=恶性胸腔积液)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d3b9807093, createdName=ssnine, createdTime=Sat Jun 22 07:00:00 CST 2013, time=2013-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626021, encodeId=56c81626021f3, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9652, encryptionId=87369652f3, topicName=IL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea8220955712, createdName=tomyang93, createdTime=Sat Jun 22 07:00:00 CST 2013, time=2013-06-22, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1778457, encodeId=0c8b1e7845778, content=<a href='/topic/show?id=51f09653ba' target=_blank style='color:#2F92EE;'>#IL-21#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9653, encryptionId=51f09653ba, topicName=IL-21)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=753a39257265, createdName=baoya, createdTime=Wed Aug 28 15:00:00 CST 2013, time=2013-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981624, encodeId=6897198162405, content=<a href='/topic/show?id=87679163e47' target=_blank style='color:#2F92EE;'>#诊断率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91637, encryptionId=87679163e47, topicName=诊断率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3bfe313, createdName=charleshjw, createdTime=Sat Mar 29 16:00:00 CST 2014, time=2014-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488627, encodeId=4f52148862e0d, content=<a href='/topic/show?id=c6af443e2d' target=_blank style='color:#2F92EE;'>#CEA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4437, encryptionId=c6af443e2d, topicName=CEA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce258462097, createdName=shizhenshan, createdTime=Sat Jun 22 07:00:00 CST 2013, time=2013-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506778, encodeId=5efb1506e78ec, content=<a href='/topic/show?id=73fc529444d' target=_blank style='color:#2F92EE;'>#恶性胸腔积液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52944, encryptionId=73fc529444d, topicName=恶性胸腔积液)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d3b9807093, createdName=ssnine, createdTime=Sat Jun 22 07:00:00 CST 2013, time=2013-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626021, encodeId=56c81626021f3, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9652, encryptionId=87369652f3, topicName=IL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea8220955712, createdName=tomyang93, createdTime=Sat Jun 22 07:00:00 CST 2013, time=2013-06-22, status=1, ipAttribution=)]
    2013-06-22 shizhenshan
  4. [GetPortalCommentsPageByObjectIdResponse(id=1778457, encodeId=0c8b1e7845778, content=<a href='/topic/show?id=51f09653ba' target=_blank style='color:#2F92EE;'>#IL-21#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9653, encryptionId=51f09653ba, topicName=IL-21)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=753a39257265, createdName=baoya, createdTime=Wed Aug 28 15:00:00 CST 2013, time=2013-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981624, encodeId=6897198162405, content=<a href='/topic/show?id=87679163e47' target=_blank style='color:#2F92EE;'>#诊断率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91637, encryptionId=87679163e47, topicName=诊断率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3bfe313, createdName=charleshjw, createdTime=Sat Mar 29 16:00:00 CST 2014, time=2014-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488627, encodeId=4f52148862e0d, content=<a href='/topic/show?id=c6af443e2d' target=_blank style='color:#2F92EE;'>#CEA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4437, encryptionId=c6af443e2d, topicName=CEA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce258462097, createdName=shizhenshan, createdTime=Sat Jun 22 07:00:00 CST 2013, time=2013-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506778, encodeId=5efb1506e78ec, content=<a href='/topic/show?id=73fc529444d' target=_blank style='color:#2F92EE;'>#恶性胸腔积液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52944, encryptionId=73fc529444d, topicName=恶性胸腔积液)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d3b9807093, createdName=ssnine, createdTime=Sat Jun 22 07:00:00 CST 2013, time=2013-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626021, encodeId=56c81626021f3, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9652, encryptionId=87369652f3, topicName=IL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea8220955712, createdName=tomyang93, createdTime=Sat Jun 22 07:00:00 CST 2013, time=2013-06-22, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1778457, encodeId=0c8b1e7845778, content=<a href='/topic/show?id=51f09653ba' target=_blank style='color:#2F92EE;'>#IL-21#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9653, encryptionId=51f09653ba, topicName=IL-21)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=753a39257265, createdName=baoya, createdTime=Wed Aug 28 15:00:00 CST 2013, time=2013-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981624, encodeId=6897198162405, content=<a href='/topic/show?id=87679163e47' target=_blank style='color:#2F92EE;'>#诊断率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91637, encryptionId=87679163e47, topicName=诊断率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3bfe313, createdName=charleshjw, createdTime=Sat Mar 29 16:00:00 CST 2014, time=2014-03-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1488627, encodeId=4f52148862e0d, content=<a href='/topic/show?id=c6af443e2d' target=_blank style='color:#2F92EE;'>#CEA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4437, encryptionId=c6af443e2d, topicName=CEA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ce258462097, createdName=shizhenshan, createdTime=Sat Jun 22 07:00:00 CST 2013, time=2013-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1506778, encodeId=5efb1506e78ec, content=<a href='/topic/show?id=73fc529444d' target=_blank style='color:#2F92EE;'>#恶性胸腔积液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52944, encryptionId=73fc529444d, topicName=恶性胸腔积液)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d3b9807093, createdName=ssnine, createdTime=Sat Jun 22 07:00:00 CST 2013, time=2013-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1626021, encodeId=56c81626021f3, content=<a href='/topic/show?id=87369652f3' target=_blank style='color:#2F92EE;'>#IL-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9652, encryptionId=87369652f3, topicName=IL-2)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea8220955712, createdName=tomyang93, createdTime=Sat Jun 22 07:00:00 CST 2013, time=2013-06-22, status=1, ipAttribution=)]
    2013-06-22 tomyang93